Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 18/20 | 0.56 |
| ▸ | DHFR | P00374 | 2/20 | 0.56 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.56 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.56 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.56 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.56 |
| ▸ | GART | P22102 | 1/20 | 0.56 |
| ▸ | ATIC | P31939 | 1/20 | 0.56 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908952 | 0.97 | TYMS (0.56) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL26019440 | 0.89 | TYMS (0.55) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19705637 | 0.88 | GART (0.74) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL16582197 | 0.87 | TYMS (0.70) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12905188 | 0.86 | TYMS (0.59) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL24629271 | 0.86 | TYMS (0.61) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL20386834 | 0.84 | TYMS (0.53) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19705636 | 0.82 | GART (0.77) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12905859 | 0.82 | TYMS (0.59) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13508147 | 0.80 | TYMS (0.55) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2019-06-20 | — | — | US | disclosed |
| US-10293053-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
| US-10293053-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TYMS 529/4885DHFR 382/4885FOLR1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.